Abstract:Organic anion transporters (OATs) and organic anion-transporting polypeptides (OATPs), encoded by a number of solute carrier (SLC)22A and SLC organic anion (SLCO) genes, mediate the absorption and distribution of drugs and other xenobiotics. The regulation of OATs and OATPs is complex, comprising both transcriptional and post-translational mechanisms. Plasma membrane expression is required for cellular substrate influx by OATs/OATPs. Thus, interest in post-translational regulatory processes, including membrane targeting, endocytosis, recycling and degradation of transporter proteins, is increasing because these are critical for plasma membrane expression. After being synthesized, transporters undergo N-glycosylation in the endoplasmic reticulum and Golgi apparatus and are delivered to the plasma membrane by vesicular transport. Their expression at the cell surface is maintained by de novo synthesis and recycling, which occurs after clathrin- and/or caveolin-dependent endocytosis of existing protein. Several studies have shown that phosphorylation by signalling kinases is important for the internalization and recycling processes, although the transporter protein does not appear to be directly phosphorylated. After internalization, transporters that are targeted for degradation undergo ubiquitination, most likely on intracellular loop residues. Epigenetic mechanisms, including methylation of gene regulatory regions and transcription from alternate promoters, are also significant in the regulation of certain SLC22A/SLCO genes. The membrane expression of OATs/OATPs is dysregulated in disease, which affects drug efficacy and detoxification. Several transporters are expressed in the cytoplasmic subcompartment in disease states, which suggests that membrane targeting/internalization/recycling may be impaired. This article focuses on recent developments in OAT and OATP regulation, their dysregulation in disease and the significance for drug therapy.

Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression

The Role of ABCB1, ABCG2, and SLC Transporters in Pharmacokinetic Parameters of Selected Drugs and Their Involvement in Drug–Drug Interactions

Post-translational modifications of transporters

ABC transporter regulation by signaling at the blood-brain barrier: relevance to pharmacology

Regulation of renal organic cation transporters

Multidrug efflux transporter ABCG2: expression and regulation

Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism

An Overview of ABC and SLC Drug Transporter Gene Regulation

Protein kinase C inhibitors: a patent review (2010 - present)

Putative role of natural products as Protein Kinase C modulator in different disease conditions

Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium

Drug Transporters in the Kidney: Perspectives on Species Differences, Disease Status, and Molecular Docking

Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease

Protein kinase C regulation of rat jejunal transport systems: mechanisms involved in bicarbonate absorption

Xenobiotic transporters: ascribing function from gene knockout and mutation studies.

Membrane transporters in drug development

The Important Role of Transporter Structures in Drug Disposition, Efficacy, and Toxicity.

Novel Mechanism of Impaired Function of Organic Anion-Transporting Polypeptide 1B3 in Human Hepatocytes: Post-Translational Regulation of OATP1B3 by Protein Kinase C Activation

The Role of Organic Cation Transporters in the Pharmacokinetics, Pharmacodynamics and Drug-Drug Interactions of Tyrosine Kinase Inhibitors

Kinase-dependent Regulation of Monoamine Neurotransmitter Transporters

Targeting Protein Kinase C for Cancer Therapy.